By Professor David Goldstein

Journal articles

Mitchison D; Butow PN; Sze M; Aldridge L; Hui R; Vardy JL; Eisenbruch M; Iedema R; Goldstein D, 2012, 'Prognostic Communication Preferences of Migrant Patients and their Relatives', Psycho-oncology, 21, pp. 496 - 504, http://dx.doi.org/10.1002/pon.1923

Butow PN; Philips F; Schweder J; White K; Underhill C; Goldstein D, 2012, 'Psychosocial well-being and supportive care needs of cancer patients living in urban and rural/regional areas: a systematic review', Supportive Care in Cancer, 20, pp. 1 - 22

Ngan SY; Burmeister B; Fisher R; Solomon M; Goldstein D; Joseph D; Ackland S; Schache D; McClure B; McLachlan S; McKendrick J; Leong T; Hartopeanu C; Zalcberg J; Mackay J, 2012, 'Randomized Trial of Short-Course Radiotherapy Versus Long-Course Chemoradiation Comparing Rates of Local Recurrence in Patients With T3 Rectal Cancer: Trans-Tasman Radiation Oncology Group Trial 01.04', Journal of Clinical Oncology, 30, pp. 3827 - 3833

Wang X; Crowe PJ; Goldstein D; Yang JL, 2012, 'STAT3 inhibition, a novel approach to enhancing targeted therapy in human cancers', International Journal of Oncology, 41, pp. 1181 - 1191, http://dx.doi.org/10.3892/ijo.2012.1568

Goldstein D; Spry N; Cummins MM; Brown C; Van Hazel GA; Carroll SL; Selva Nayagam S; Borg M; Ackland S; Wratten C; Shapiro J; Porter L; Hruby G; Horvath LG; Bydder S; Underhill C; Harvey JE; Gebski V, 2012, 'The GOFURTGO Study: AGITG Phase II Study of fixed dose rate gemcitabine-oxaliplatin integrated with concomitant 5FU and 3-D conformal radiotherapy for the treatment of localised pancreatic cancer', British Journal of Cancer, 106, pp. 61 - 69, http://dx.doi.org/10.1038/bjc.2011.526

Luckett T; Goldstein D; Butow PN; Gebski V; Aldridge LJ; McGrane J; Ng W; King MT, 2011, 'Psychological morbidity and quality of life of ethnic minority patients with cancer: A systematic review and meta-analysis', The Lancet Oncology, 12, pp. 1240 - 1248, http://dx.doi.org/10.1016/S1470-2045(11)70212-1

Peng J; Shi D; Goodman KA; Goldstein D; Xiao C; Guan Z; Cai S, 2011, 'Early results of quality of life for curatively treated rectal cancers in Chinese patients with EORTC QLQ-CR29', Radiation Oncology, 6, pp. 93, http://dx.doi.org/10.1186/1748-717X-6-93

Butow PN; Goldstein D; Bell ML; Sze M; Aldridge LJ; Abdo S; Tanious M; Dong S; Iedema R; Vardy J; Ashgari R; Hui R; Eisenbruch M, 2011, 'Interpretation in consultations with immigrant patients with cancer: How accurate is it?', Journal of Clinical Oncology, 29, pp. 2801 - 2807, http://dx.doi.org/10.1200/JCO.2010.34.3335

Webber K; Mok K; Bennett BK; Juraskova I; Goldstein D; Friedlander M; Lloyd AR; FOLCAN study group , 2011, 'Cancer-related fatigue and sexual functioning in women with early breast cancer: Is there a link?', J Clin Oncol, 29, pp. 9072, http://www.ncbi.nlm.nih.gov/pubmed/28021533

Hammel P; Huguet F; Van Laethem J; Goldstein D; Glimelius B; Moore MJ; Chibaudel B; Bonnetain F; Louvet C, 2011, 'Randomized multicenter phase III study in patients with locally advanced adenocarcinoma of the pancreas: Gemcitabine with or without chemoradiotherapy and with or without erlotinib—LAP 07 study.', Journal of Clinical Oncology, 29, pp. e14619 - e14619, http://dx.doi.org/10.1200/jco.2011.29.15_suppl.e14619

Goldstein D; Lee C; Tracey E; Cook-Yarborough C; Lord S, 2011, 'Validating innovation: A population-based study of gastrointestinal stromal tumors (GIST) to estimate the survival benefit of imatinib.', J Clin Oncol, 29, pp. 10060, http://www.ncbi.nlm.nih.gov/pubmed/28021288

Arun SJ; Xu Z; Fiala-Beer E; Phillips P; Goldstein D; Biankin A; Pirola R; Wilson JS; Apte MV, 2011, 'Hepatocyte growth factor: a potential therapeutic target in pancreatic cancer', CANCER RESEARCH, 71, http://dx.doi.org/10.1158/1538-7445.AM2011-LB-395

Yang JL; DasGupta R; Hopkins A; Luk F; Goldstein D; Crowe P, 2011, 'Significance of IGF-1R and Its signaling pathways in human sarcoma', CANCER RESEARCH, 71, http://dx.doi.org/10.1158/1538-7445.AM2011-4416

Goldstein D; Gainford MC; Brown C; Tebbutt N; Ackland SP; Van Hazel G; Jefford M; Abdi E; Selva-Nayagam S; Gebski V; Miller D; Shannon J, 2011, 'Fixed-dose-rate gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas', Cancer Chemotherapy and Pharmacology, 67, pp. 519 - 525, http://dx.doi.org/10.1007/s00280-010-1351-8

Clarke SJ; Yip S; Brown C; Van Hazel GA; Ransom DT; Goldstein D; Jeffrey GM; Tebbutt NC; Buck M; Lowenthal RM; Boland A; Gebski V; Zalcberg J; Simes RJ, 2011, 'Single-agent irinotecan or 5-fluorouracil and leucovorin (FOLFIRI) as second-line chemotherapy for advanced colorectal cancer; Results of a randomised phase II study (DaVINCI) and meta-analysis', European Journal of Cancer, 47, pp. 1826 - 1836, http://dx.doi.org/10.1016/j.ejca.2011.04.024

Zhi J; Major P; Chen E; Burns I; Robinson B; McKendrick J; Rittweger K; Abt M; Goldstein D, 2011, 'A multi-centre, randomised, open-lable study to assess the steady state paramacokinetics of Bevacizumab given with either Xeloda or FOLFOX-4 in patient with metastatic colorectal cancer', Cancer Chemotherapy and Pharmacology, 68, pp. 1199 - 1206

Sjoquist KM; Goldstein D; Bester L; Bester L, 2011, 'A serious complication of selected internal radiation therapy: case report and literature review', Oncologist, 15, pp. 830 - 835

Park SB; Lin CS-Y; Krishnan AV; Goldstein D; Friedlander M; Kiernan MC, 2011, 'Dose effects of Oxaliplatin on persistent and transient na+ conductances and the development of neurotoxicity', PLoS One, 6, pp. 1 - 7, http://dx.doi.org/10.1371/journal.pone.0018469

Goldstein D; Gainford M; Brown C; Tebbutt N; Ackland S; Van Hazel GA; Jefford M; Abdi E; Gebski V; Miller D; Shannon JF, 2011, 'Fixed dose rate gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas', Cancer Chemotherapy and Pharmacology, 16, pp. 519 - 519

Goldstein D; Butow P; Sze M; Mikhail M; Eisenbruch M, 2011, 'Grappling with cultural differences; Communication between oncologists and immigrant cancer patients with and without interpreters', Patient Education and Counseling, 84, pp. 398 - 405

Webber K; Mok K; Bennett BK; Lloyd AR; Friedlander M; Juraskova I; Goldstein D, 2011, 'If I Am in the Mood, I Enjoy It: an exploration of cancer-related fatigue and sexual functioning in women with breast cancer', Oncologist, 16, pp. 1333 - 1344

Park SB; Lin CS-Y; Krishnan AV; Goldstein D; Friedlander M; Kiernan MC, 2011, 'Long-term neuropathy after Oxaliplatin treatment: Challenging the dictum of reversibility', Oncologist, 16, pp. 708 - 716, http://dx.doi.org/10.1634/theoncologist.2010-0248

Webber K; Cooper A; Kleiven H; Yip D; Goldstein D, 2011, 'Management of metastatic renal cell carcinoma in the era of targeted therapies', Internal Medicine Journal, 41, pp. 594 - 605

Park SB; Goldstein D; Lin CS-Y; Krishnan AV; Friedlander M; Kiernan MC, 2011, 'Neuroprotection for oxaliplatin-induced neurotoxicity: what happened to objective assessment?', Journal of clinical oncology - official journal of the American Society of Clinical Oncology, 29, pp. e553 - e554e

Luckett T; Goldstein D; Butow PN; Gebski V; Aldridge L; McGrane J; Ng W; King MT, 2011, 'Psychological morbidity and quality of life of ethnic minority patients with cancer: a systematic review and meta-analysis', Lancet Oncology, 12, pp. 1240 - 1248, http://dx.doi.org/10.1016/S1470

Wirth A; Grigg A; Wolf M; Goldstein D; Johnson C; Davis S; Dutu G; Kypreos P; Smith C; Kneebone A; Herzberg M; Joseph D; Catalano J; Roos DE; Stone J; Reynolds J, 2011, 'Risk and response adapted therapy for early stage Hodgkin lymphoma: a prospective multicenter study of the Australasian Leukaemia and Lymphoma Group/Trans-Tasman Radiation Oncology Group', Leukemia and Lymphoma, 52, pp. 786 - 795, http://dx.doi.org/10.3109/10428194.2010.547155

Tebbutt N; murphy F; Zannino D; Wilson D; Cummins MM; Abdi E; Strickland A; Lowenthal RM; Marx G; Karapetis C; Shannon JF; Goldstein D; Nayagam SS; Blum R; Chantrill L; Simes RJ; Price T, 2011, 'Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab', Annals of Oncology, 22, pp. 1834 - 1838

Leighl N; Shepherd H; Butow PN; clarke SJ; Mcjannett M; Beale P; Wilken N; Moore M; Chen E; Goldstein D; Horvath LG; Knox J; Krzyzanowska M; Oza AM; Feld R; Hedley D; Xu W; Tattersall MH, 2011, 'Supporting treatment decision-making in advanced cancer: a randomized trial of a decision aid for patients considering chemotherapy in advanced colorectal cancer', Journal of Clinical Oncology, 29, pp. 2077 - 2084, http://dx.doi.org/10.1200/JCO.2010.32.0754

Park SB; Lin CS-Y; Krishnan AV; Goldstein D; Friedlander M; Kiernan MC, 2011, 'Utilizing natural activity to dissect the pathophysiology of acute oxaliplatin-induced neuropathy', Experimental Neurology, 227, pp. 120 - 127, http://dx.doi.org/10.1016/j.expneurol.2010.10.002

Tebbutt NC; Wilson K; Gebski VJ; Cummins MM; Zannino D; Van Hazel GA; Robinson B; Broad A; Ganju V; Ackland SP; Forgeson G; Cunningham D; Saunders MP; Stockler MR; Chua Y; Zalcberg JR; Simes RJ; Price TJ; Coates A; O'Connell D; Brown C; Hague W; France A; Hicks S; James R; Masson R; O'Connell R; Pike R; Shoulder J; Stevens L; Tunney V; Vachan B; Wong N; Ackland S; Moylan E; Strickland A; Abdi E; Ransom D; Lowenthal R; Marx G; Nayagam SS; Shannon J; Goldstein D; Karapetis C; Blum R; Eek R; Ward R; Pavlakis N; Wilcken N; Burns I; Wyld D; Underhill C; Claringbold P; Liauw W; Clingan P; Jefford M; Horvath L; McKendrick J; Chong G; Boyce A; Cassidy J; Kirsten F; Clarke S; Guo Y; Innes-Rowe J; Smith A; Williams J; Tournier E; Maliepaard S; Vitullo E; Humm G; Nguyen V; Midolo P; Chorlton C; McDonald L; Oliver L; Sjursen AM; Inglis C; Marafioti T; McCourt J; Howard J; Richards A; Provis A; Rundle A; Whatman A; Emmett L; Raymond B; Byrne S; Withers E; Campbell J; Hodgkins C; Szwajcer M; Parker S; Welby S; Page F; Corker M; Wykes R; Goss C; Whitney S; Oates J, 2010, 'Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: Results of the Australasian Gastrointestinal Trials Group randomized phase III MAX study', Journal of Clinical Oncology, 28, pp. 3191 - 3198, http://dx.doi.org/10.1200/JCO.2009.27.7723

Ngan S; Fisher R; Goldstein D; Solomon M; Burmeister B; Ackland SP; Joseph DJ; McClure B; McLachlan S; Mackay J, 2010, 'A randomized trial comparing local recurrence (LR) rates between short-course (SC) and long-course (LC) preoperative radiotherapy (RT) for clinical T3 rectal cancer: An intergroup trial (TROG, AGITG, CSSANZ, RACS).', Journal of Clinical Oncology, 28, pp. 3509 - 3509, http://dx.doi.org/10.1200/jco.2010.28.15_suppl.3509

Webber K; Goldstein D; Bennett BK; Boyle FM; De Souza PL; Wilcken N; Friedlander M; Lloyd AR, 2010, 'Influence of fatigue after breast cancer adjuvant theraphy on health care utilization and percieved needs', JOURNAL OF CLINICAL ONCOLOGY, 28, http://dx.doi.org/10.1200/jco.2010.28.15_suppl.9047

Tebbutt NC; Kotasek D; Burris HA; Schwartzberg LS; Hurwitz H; Stephenson J; Adewoye H; Sun Y; Ye Y; Goldstein D, 2010, 'Motesanib with or without panitumumab (pmab) plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer (mCRC).', Journal of Clinical Oncology, 28, pp. 3538 - 3538, http://dx.doi.org/10.1200/jco.2010.28.15_suppl.3538

Klumpen H; Eechoute K; Hertzberg MS; Schwarer AA; Goldstein D; Hughes TP; Liddle C; Mathijssen R; Schellens JH; Gurney H, 2010, 'Pharmacogenetic factors predicting the need for a higher dose of imatinib.', Journal of Clinical Oncology, 28, pp. 3098 - 3098, http://dx.doi.org/10.1200/jco.2010.28.15_suppl.3098

Chua YJ; Michael M; Zalcberg JR; Hicks RJ; Goldstein D; Liauw W; Price T, 2010, 'Antitumor effect of somatostatin analogs in neuroendocrine tumors', Journal of Clinical Oncology, 28, http://dx.doi.org/10.1200/JCO.2009.26.0612

Lovell MR; Forder PM; Stockler MR; Butow P; Briganti EM; Chye R; Goldstein D; Boyle FM, 2010, 'A randomized controlled trial of a standardized educational intervention for patients with cancer pain', Journal of Pain and Symptom Management, 40, pp. 49 - 59, http://dx.doi.org/10.1016/j.jpainsymman.2009.12.013

Park SB; Lin CS-Y; Krishnan AV; Goldstein D; Friedlander ML; Kiernan MC, 2010, '5. A novel biomarker of axonal dysfunction in oxaliplatin-induced neurotoxicity', Clinical Neurophysiology, 121, pp. e2 - e2, http://dx.doi.org/10.1016/j.clinph.2009.10.025

Goldstein D; Butow PN; Boyle F; Stockler M; Lovell M; Chye R; Forder P; Briganti E, 2010, 'A randomized controlled trial of a standardized educational intervention for patients with cancer pain', Journal of Pain and Symptom Management, 49, pp. 49 - 59

Blinman P; Duric V; Nowak A; Beale P; Clarke SJ; Briscoe K; Boyce A; Goldstein D; Hudson M; Stockler M, 2010, 'Adjuvant chemotherapy for early colon cancer: what survival benefits make it worthwhile?', European Journal of Cancer, 46, pp. 1800 - 1807

Neoptolemos J; stocken D; bassi C; Goldstein D, 2010, 'Adjuvant chemotherapy with flurouracil plus folinic acid vs gemcitabine following pancreatic cancer resection:a randomsied trial JAMA 2010', JAMA - Journal of the American Medical Association, 304, pp. 1073 - 1081

Butow PN; Sze M; Dugal-beri P; Mikhail M; Eisenbruch M; Jefford M; Schofield P; Girgis A; king M; Goldstein D, 2010, 'From inside the bubble: Migrants' perceptions of communication with the cancer tea', Supportive Care in Cancer, 19, pp. 281 - 290

Goldstein D; Gill A; Chou A; Vilain R; Clarkson A; Lui M; Jin R; Tobias VH; Samral J; Smith C; Sioson L; Parker N; Smith R; Sywak M; Wyatt S; Robinson B; Eckstein R; Benn D; Clifton-bligh R, 2010, 'Immunohistochemistry for SDHB divides gastrointestinal stromal tumours (GISTs) into two distinct types', American Journal of Surgical Pathology, 34, pp. 636 - 644

Goldstein D; Ackland S; Van Hazel GA; Jefford M; Shannon JF; Gainford M; Brown C; Abdi E; Miller D; Gebski V; Tebbutt N, 2010, 'Optimising the benefit: a phase II trial of Gemcitabine in fixed dose rate infusion combined with Cisplatin in patients with inoperable biliary tract carcinomas', Cancer Chemotherapy and Pharmacology

Goldstein D; Underhill CR; Olver IN; Kosczwara ; Kay F; Franca M, 2010, 'Reaching Further with Online Education? The Development of an Effective Online Program in Palliative Oncology', Journal of Cancer Education, 25, pp. 317 - 323

Wolf M; Kneebone AB; Goldstein D; Joseph D; Wirth A; Grigg A; Johnson C; Davis S, 2010, 'Risk and Response Adapted Therapy for Early Stage Hodgkin Lymphoma: A Prospective Multi-Centre Study of the Australasian Leukaemia and Lymphoma Group/Trans-Tasman Radiation Oncology Group', Leukemia and Lymphoma, 52, pp. 786 - 795, http://dx.doi.org/10.3109/10428194.2010.547155

Xu ZH; Vonlaufen A; Phillips PA; Fiala-Beer E; Zhang X; Yang L; Biankin AV; Goldstein D; Pirola R; Wilson JS; Apte MV, 2010, 'Role of pancreatic stellate cells in pancreatic cancer metastasis', American Journal of Pathology, 177, pp. 2585 - 2596, http://linkinghub.elsevier.com/retrieve/pii/S0002-9440(10)60308-2

Goldstein D; Harris C; Harris C, 2010, 'Tamoxifen use in retroperitoneal fibrosis, case report and review of the literature', Internal Medicine Journal, 40, pp. e5 - e7

Harris C; Goldstein D, 2010, 'Tamoxifen use in retroperitoneal fibrosis.', Intern Med J, 40, pp. e5 - e7, http://dx.doi.org/10.1111/j.1445-5994.2010.02373.x

Rossleigh MA; Goldstein D, 2010, 'Treatment of Fluorouracil-Refractory Patients with Liver Metastases from Colorectal Cancer by Using Yttrium-90 Resin Microspheres Plus Concomitant Systemic Irinotecan Chemotherapy', Journal of Clinical Oncology, 27, pp. 4089 - 4095

Xu Z; Phillips PA; Vonlaufen A; Fiala-Beer E; Yang L; Biankin A; Goldstein D; Pirola R; Wilson J; Apte M, 2009, 'Normal Pancreatic Stellate Cells Facilitate Pancreatic Cancer Progression, Exhibit Transendothelial Migration and Accompany Cancer Cells to Distant Metastatic Sites', PANCREAS, 38, pp. 1062 - 1062, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000271225300403&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Back to profile page